SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

Home   |   Publication   |   SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
Publications
75 +
Clinical Trials Ran
0 +
Approved Therapies
0

Areas of Expertise